• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down1.54% Nasdaq Down1.52%

    Neuralstem, Inc. (CUR)

    2.03 Down 0.15(6.88%) Apr 17, 4:00PM EDT
    |After Hours : 2.03 0.00 (0.00%) Apr 17, 4:00PM EDT
    Add to Portfolio
    ProfileGet Profile for:
    Neuralstem, Inc.
    20271 Goldenrod Lane
    Germantown, MD 20876
    United States - Map
    Phone: 301-366-4841
    Website: http://www.neuralstem.com

    Index Membership:N/A
    Full Time Employees:21

    Business Summary 

    Neuralstem, Inc., a biopharmaceutical company, focuses on the development and commercialization of regenerative medicine treatments based on its human neuronal stem cells and small molecule compounds. The company’s stem cell technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of all types. Its clinical program products include NSI-566, which is in ongoing Phase II clinical trials for the treatment of amyotrophic lateral sclerosis, as well as in Phase I clinical trial for chronic spinal cord injury. The company’s clinical development products also comprise NSI–566 that is in Phase I/II clinical trials for motor deficits due to ischemic stroke in China; NSI–189 that completed Phase Ia and Ib trials for the treatment of major depressive disorders; and NSI–189, which is in Phase Ib preparation for cognitive deficit in schizophrenia. Neuralstem, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Neuralstem, Inc.

    Corporate Governance 
    Neuralstem, Inc.’s ISS Governance QuickScore as of Apr 1, 2015 is 8. The pillar scores are Audit: 1; Board: 6; Shareholder Rights: 6; Compensation: 10.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Dr. Karl Y. Johe Ph.D., 55
    Co-Founder, Chairman and Chief Scientific Officer
    Mr. I. Richard Garr J.D., 62
    Co-Founder, Chief Exec. Officer, Pres, Chief Financial Officer, Principal Accounting Officer, Gen. Counsel and Director
    Dr. Thomas Hazel Ph.D.,
    Sr. VP of Research
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders